Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

This trial is open and accepting eligible patients.

Trial Overview

The goal of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of ixazomib given as part of a combination therapy to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma. More specifically, the study is focused on subjects who were previously treated with bortezomib (Velcade®) or carfilzomib (Kyprolis®) and showed worsening of their myeloma while receiving either one of these drugs in combination therapy. This study is a Phase I/II. Ixazomib is an investigational drug, which means that ixazomib is currently being tested and is not yet approved by the United States Food and Drug Administration (FDA) for subjects with relapsed or refractory multiple myeloma. Ixazomib is a new study drug that belongs to the same class as bortezomib and carfilzomib; however, unlike bortezomib and carfilzomib, ixazomib is taken by mouth. Current studies investigating ixazomib are demonstrating that it is as safe as bortezomib and effective for the treatment of multiple myeloma both on its own and in combination with other multiple myeloma medications, such as lenalidomide and dexamethasone, or prednisone and melphalan.


What is the phase of this trial?

Phase 1/2 what does this mean

What type of trial is this?

This is an interventional trial. This type of trial actively treats your myeloma.

What treatments are used in this trial?
Trial Locations

There are 4 trial sites around the United States.
Find the closest trial site.

How many patients will participate in this trial?

Approximately 60 patients will be enrolled in this study.

Who is sponsoring this trial?

Oncotherapeutics

SparkCures Trial Identifiers

MM-0677 , NCT02206425 what is this

4 US locations

Am I Eligible For This Trial?

All clinical trials provide reasons that patients may or may not be able to join called 'eligibility criteria'. The following is a high-level eligibility criteria provided by the sponsor of this trial. Additional eligibility criteria may apply.

Trial Contact Information

For study information, please contact Fritz Costa at (310) 623-3154.

Trial locations are sorted by state. Enter your zip code to sort by closest distance.

California

James R Berenson, MD, Inc.

9201 W. Sunset Boulevard, Suite 310, West Hollywood, CA 90069

This site is open and accepting eligible patients.


California Cancer Associates for Research & Excellence, Inc. (cCARE)

477 N. El Camino Real, Suite D200, Encinitas, CA 92024

This site is open and accepting eligible patients.


John Muir Medical Center

2540 East Street, Concord, CA 94520

This site is open and accepting eligible patients.


Illinois

Oncology Specialists S.C.

7900 Milwaukee Avenue, Suite 16, Niles, IL 60714

This site is open and accepting eligible patients.


There are 4 active US locations.